PhoreMost and Ligand Subsidiary Vernalis Limited Announce Drug Discovery Collaboration for Novel Oncology Target 12th June 2019
PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programs 21st June 2018
PhoreMost and NeoPhore Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme 27th April 2018
PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company 15th November 2017